Tango Therapeutics GAAP EPS of -$0.32 misses by $0.04, revenue of $5.43M misses by $2.81M

• Tango Therapeutics press release (NASDAQ:TNGX): Q4 GAAP EPS of -$0.32 misses by $0.04.
• Revenue of $5.43M (-15.3% Y/Y) misses by $2.81M.

More on Tango Therapeutics

• Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs
• Tango Therapeutics Must Produce Its Own Data To Justify Its Valuation
• Seeking Alpha’s Quant Rating on Tango Therapeutics
• Historical earnings data for Tango Therapeutics
• Financial information for Tango Therapeutics